Skip to main content
Premium Trial:

Request an Annual Quote

Enzo's Q4 Revenues Fall, Losses Widen; Company to Recognize $2M From Sigma Settlement in Q1 '07

NEW YORK (GenomeWeb News) - Enzo Biochem on Friday reported an 8.7-percent decline in revenues atop a widened net loss for its fourth fiscal quarter.
For the quarter ended July 31, Enzo posted revenues of $9.9 million, down from $10.9 million in the year-ago period.
The company’s quarterly net loss more than doubled to $4.5 million from $2 million in the fourth quarter of 2005.
Enzo attributed the swelling net loss to a $900,000 increase in expenses, including a $500,000 increase in R&D expenses. The balance of the spending increase went toward litigation expenses and selling, general, and administrative expenses, the company said.
In its 10-K report filed with the US Securities and Exchange Commission, the company said that it would recognize $2 million from a recent settlement with Sigma-Aldrich in its first fiscal quarter for 2007, ending Oct. 31.
Enzo did not disclose its R&D spending for the quarter.  
As of July 31, Enzo had cash , cash equivalents, and marketable securities of $69.9 million.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.